Drug and gene delivery to the back of the eye: from bench to bedside.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Investigative Ophthalmology and Visual Science

• Publication date

  2014-04-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1167/iovs.13-13707PMID 24777644PMCID PMC4004426
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease.

  2013cited by this paper
• Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors

  2013cited by this paper
• Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2.

  2013cited by this paper
• Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab.

  2013cited by this paper
• The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection.

  2012cited by this paper
• Comparative Analysis of DNA Nanoparticles and AAVs for Ocular Gene Delivery

  2012cited by this paper
• Best practices for treatment of retinal vein occlusion

  2012cited by this paper
• Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs.

  2012cited by this paper
• Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye.

  2012cited by this paper
• Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration.

  2012cited by this paper
• Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.

  2012cited by this paper
• Blood-Retinal Barrier

  2011cited by this paper
• Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells.

  2011cited by this paper
• Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure.

  2011cited by this paper
• Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness.

  2011cited by this paper
• Transport of hepcidin, an iron-regulatory peptide hormone, into retinal pigment epithelial cells via oligopeptide transporters and its relevance to iron homeostasis.

  2011cited by this paper
• Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease.

  2011cited by this paper
• Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema.

  2011cited by this paper
• Evidence for two different broad-specificity oligopeptide transporters in intestinal cell line Caco-2 and colonic cell line CCD841.

  2011cited by this paper
• Retinal Degeneration Progression Changes Lentiviral Vector Cell Targeting in the Retina

  2011cited by this paper
• Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models.

  2011cited by this paper
• Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

  2010cited by this paper
• Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin.

  2010cited by this paper
• Gene delivery to mitotic and postmitotic photoreceptors Via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa

  2010cited by this paper
• Identification of a novel sodium-coupled oligopeptide transporter (SOPT2) in mouse and human retinal pigment epithelial cells.

  2010cited by this paper
• The global economic cost of visual impairment

  2010cited by this paper
• Ocular Delivery of Compacted DNA-Nanoparticles Does Not Elicit Toxicity in the Mouse Retina

  2009cited by this paper
• Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.

  2009cited by this paper
• Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV

  2009cited by this paper
• High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors.

  2009cited by this paper
• Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina.

  2009cited by this paper
• Investigating the Movement of Intravitreal Human Serum Albumin Nanoparticles in the Vitreous and Retina

  2009cited by this paper
• Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration

  2008cited by this paper
• Safety and efficacy of gene transfer for Leber's congenital amaurosis.

  2008cited by this paper
• Factors affecting perceptual thresholds in epiretinal prostheses.

  2008cited by this paper
• Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial

  2008cited by this paper
• Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.

  2008cited by this paper
• Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics

  2008cited by this paper
• Effect of gene therapy on visual function in Leber's congenital amaurosis.

  2008cited by this paper
• Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations

  2008cited by this paper
• Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.

  2008cited by this paper
• Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir.

  2008cited by this paper
• Adult vitreous structure and postnatal changes

  2008cited by this paper
• Two Teams Report Progress in Reversing Loss of Sight

  2008cited by this paper
• Perspective on genes and mutations causing retinitis pigmentosa.

  2007cited by this paper
• Surface engineering of quantum dots for in vivo vascular imaging.

  2007cited by this paper
• Visual performance using a retinal prosthesis in three subjects with retinitis pigmentosa.

  2007cited by this paper
• Retinal prostheses: current challenges and future outlook

  2007cited by this paper
• Timing and computation in inner retinal circuitry.

  2007cited by this paper
• Commentary: An Aye for Eye Gene Therapy

  2006cited by this paper
• A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.

  2006cited by this paper
• Parallel processing in retinal ganglion cells: how integration of space-time patterns of excitation and inhibition form the spiking output.

  2006cited by this paper
• Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration.

  2006cited by this paper
• Ocular drug delivery

  2006cited by this paper
• Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles

  2006cited by this paper
• Vitamin A palmitate and aciclovir biodegradable microspheres for intraocular sustained release.

  2006cited by this paper
• Age-related changes in human vitreous structure

  2005cited by this paper
• Topical and systemic drug delivery to the posterior segments.

  2005cited by this paper
• Millisecond-timescale, genetically targeted optical control of neural activity

  2005cited by this paper
• Compacted DNA Nanoparticles Administered to the Nasal Mucosa of Cystic Fibrosis Subjects Are Safe and Demonstrate Partial to Complete Cystic Fibrosis Transmembrane Regulator Reconstitution

  2004cited by this paper
• RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW

  2004cited by this paper
• Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea

  2003cited by this paper
• Retinal remodeling in inherited photoreceptor degenerations

  2003cited by this paper
• On the genetics of retinitis pigmentosa and on mutation‐independent approaches to therapeutic intervention

  2002cited by this paper
• Vertical interactions across ten parallel, stacked representations in the mammalian retina

  2001cited by this paper
• Microdialysis Evaluation of the Ocular Pharmacokinetics of Propranolol in the Conscious Rabbit

  1999cited by this paper
• Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice

  1997cited by this paper
• Identification of a Gene That Causes Primary Open Angle Glaucoma

  1997cited by this paper
• Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning.

  1995cited by this paper
• MOVEMENT OF ALBUMIN AND DEXTRAN THROUGH THE SCLERA.

  1965cited by this paper

• Toward a New Frontier in Diabetic Retinopathy Treatment: A Synergistic Approach Using Gene Therapy and Nanotechnology

  2025cites this paper
• Formulation and characterization of transfersomes for ocular delivery of tonabersat

  2025cites this paper
• Nanomaterial-Based Anti-Angiogenic Gene Therapy for Retinal Neovascular Diseases: Mechanistic Insights and Preclinical Advances

  2025cites this paper
• Targeting the NLRP3 Inflammasome: Pharmacological Mechanisms for the Treatment of Dry Eye Disease.

  2025cites this paper
• A Model of the Mechanisms Underpinning Unconventional Aqueous Humor Outflow

  2025cites this paper
• External stimuli-responsive drug delivery to the posterior segment of the eye

  2025cites this paper
• Fluorinated multifunctional polymer vesicles for enhanced ocular surface penetration and synergistic treatment of dry eye disease.

  2025cites this paper
• Non-Viral Delivery Systems to Transport Nucleic Acids for Inherited Retinal Disorders

  2025cites this paper
• Nanotherapy for Neural Retinal Regeneration

  2025cites this paper
• Retinal Ganglion Cell Transplantation: Differentiation and Quantification Strategies.

  2025cites this paper
• Biotechnological Novel Drug Delivery Systems for Age-Related Macular Degeneration.

  2025cites this paper
• Nanotechnology-Based Delivery Systems and Retinal Pigment Epithelium: Advances, Targeting Approaches, and Translational Challenges

  2025cites this paper
• A Clinical, Pharmacological, and Formulation Evaluation of Melatonin in the Treatment of Ocular Disorders—A Systematic Review

  2024cites this paper
• H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration

  2024cites this paper
• Development of dexamethasone suspension eye drops: A comparative investigation of ternary and quaternary cyclodextrin aggregates

  2023cites this paper
• Liposome-polyethylenimine complexes for the effective delivery of HuR siRNA in the treatment of diabetic retinopathy

  2023cites this paper
• International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs

  2023cites this paper
• Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection

  2023influential citation
• Noninvasive Framework Nucleic Acid Eye Drops for Retinal Administration.

  2023cites this paper
• Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies

  2023cites this paper
• AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery

  2023cites this paper
• Ocular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies.

  2023cites this paper
• Suppression of NLRP3/Caspase-1/GSDMD Mediated Corneal Epithelium Pyroptosis Using Melatonin-Loaded Liposomes to Inhibit Benzalkonium Chloride-Induced Dry Eye Disease

  2023cites this paper
• Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration

  2023cites this paper
• Biodistribution of Cy5-labeled Thiolated and Methylated Chitosan-Carboxymethyl Dextran Nanoparticles in an Animal Model of Retinoblastoma

  2022cites this paper
• Ophthalmic dosage forms for drug delivery to posterior segment

  2022cites this paper
• Topical Drug Delivery to the Posterior Segment of the Eye

  2022cites this paper
• Cellular and subcellular optogenetic approaches towards neuroprotection and vision restoration.

  2022cites this paper
• Nanomedicine and drug delivery to the retina: current status and implications for gene therapy

  2022cites this paper
• Long-acting drug delivery systems for ocular therapies

  2022cites this paper
• Therapeutic nanocoating of ocular surface

  2021cites this paper
• Analysis of topical dosing and administration effects on ocular drug delivery in a human eyeball model using computational fluid dynamics

  2021cites this paper
• Antisense Oligonucleotide Therapeutics for Neurodegenerative Disorders

  2021cites this paper
• New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review

  2021cites this paper
• The EyeFlowCell: Development of a 3D-Printed Dissolution Test Setup for Intravitreal Dosage Forms

  2021cites this paper
• Emerging innovations in nano-enabled therapy against age-related macular degeneration: A paradigm shift.

  2021cites this paper
• Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment

  2021cites this paper
• Ophthalmic Magnetic Resonance Imaging: Where Are We (Heading To)?

  2021cites this paper
• Nanotechnology-Abetted Astaxanthin Formulations in Multimodel Therapeutic and Biomedical Applications

  2021cites this paper
• Ocular Suspension and Nanosuspension Products: Formulation Development Considerations

  2021cites this paper
• Therapies Based on Nanoparticles for Eye Drug Delivery

  2020cites this paper
• Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations

  2020cites this paper
• PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats.

  2020cites this paper
• Intravitreal hydrogels for sustained release of therapeutic proteins.

  2020cites this paper
• Selected Aspects of Ocular Toxicity Studies With a Focus on High-Quality Pathology Reports: A Pathology/Toxicology Consultant’s Perspective

  2020cites this paper
• Rosmarinic Acid Intravitreal Implants: A New Therapeutic Approach for Ocular Neovascularization

  2020cites this paper
• Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies

  2020cites this paper
• Advances in chemistry and composition of soft materials for drug releasing contact lenses

  2020cites this paper
• Nonclinical Safety Assessment of FHTR2163, An Antigen-Binding Fragment Against HTRA1 for the Treatment of Geographic Atrophy

  2020cites this paper
• Suprachoroidal Injection of Triamcinolone- Review of a Novel Treatment for Macular Edema Caused by Noninfectious Uveitis.

  2020cites this paper
• Current Advances in Ophthalmic Technology

  2020cites this paper
• Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations

  2020cites this paper
• Triamcinolone Acetonide-Loaded PEGylated Microemulsion for the Posterior Segment of Eye

  2020cites this paper
• Preclinical challenges for developing long acting intravitreal medicines.

  2020cites this paper
• Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges

  2019cites this paper
• Formulation Strategies to Address Physiological and Anatomical Constraints for Improved Topical Ocular Drug Delivery

  2019cites this paper
• Newer Technologies in Vitreoretinal Disorders

  2019cites this paper
• Overcoming the anatomical and physiological barriers in topical eye surface medication using peptide-decorated-polymeric micelle.

  2019cites this paper
• Collagenase injection into the suprachoroidal space of the eye to expand drug delivery coverage and increase posterior drug targeting.

  2019cites this paper
• Special Section on Drug Delivery Technologies Gellan Gum Based Sol-to-Gel Transforming System of Natamycin Transfersomes Improves Topical Ocular Delivery

  2019cites this paper
• Establishment of a multilayered 3D cellular model of the retinal-blood barrier.

  2019cites this paper
• Nanotechnology in regenerative ophthalmology.

  2019cites this paper
• Gene Therapy in Retinal Dystrophies

  2019cites this paper
• Gellan Gum Based Sol-to-Gel Transforming System of Natamycin Transfersomes Improves Topical Ocular Delivery

  2019cites this paper
• Targeting drug delivery within the suprachoroidal space.

  2019cites this paper
• The obstacle course to the inner retina: Hyaluronic acid-coated lipoplexes cross the vitreous but fail to overcome the inner limiting membrane.

  2019cites this paper
• In vivo MRI assessment of bioactive magnetic iron oxide/human serum albumin nanoparticle delivery into the posterior segment of the eye in a rat model of retinal degeneration

  2019cites this paper
• Visible light wavefront sensorless adaptive optics optical coherence tomography

  2018cites this paper
• Ion-sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: in vitro permeability, cytotoxicity and in vivo evaluation

  2018cites this paper
• The suprachoroidal space as a route of administration to the posterior segment of the eye☆

  2018cites this paper
• Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle

  2018cites this paper
• Targeted Drug Delivery in the Suprachoroidal Space by Swollen Hydrogel Pushing

  2018cites this paper
• Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina

  2018cites this paper
• Safety Assessment of Formulation Vehicles Following Intravitreal Administration in Rabbits

  2018cites this paper
• 7.1 T MRI and T2 mapping of the human and porcine vitreous body post mortem

  2018cites this paper
• A review on recent drug delivery systems for posterior segment of eye.

  2018cites this paper
• Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases

  2018cites this paper
• Topical Formulation of Self-Assembled Antiviral Prodrug Nanomicelles for Targeted Retinal Delivery.

  2017cites this paper
• Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit

  2017cites this paper
• Topical Ocular Delivery of TGF-β1 to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases

  2017cites this paper
• Non-viral strategies for ocular gene delivery.

  2017cites this paper
• Discerning the composition of penetratin for safe penetration from cornea to retina.

  2017cites this paper
• In vitro and ex vivo models to study drug delivery barriers in the posterior segment of the eye☆

  2017cites this paper
• Pharmacologic Therapy of Ocular Disease

  2017cites this paper
• Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration

  2017cites this paper
• Principles of pharmacology in the eye

  2017cites this paper
• Pharmacokinetic aspects of retinal drug delivery.

  2017cites this paper
• Recent perspectives on the delivery of biologics to back of the eye

  2017cites this paper
• Photopharmacological control of bipolar cells restores visual function in blind mice

  2017cites this paper
• Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space

  2017cites this paper
• Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol.

  2017cites this paper
• A minimally invasive adjustable‐depth blunt injector for delivery of pharmaceuticals into the posterior pole

  2017cites this paper
• Ocular Drug Delivery.

  2017cites this paper
• Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics

  2017cites this paper
• Thrombospondin‐derived peptide attenuates Sjögren's syndrome‐associated ocular surface inflammation in mice

  2017cites this paper
• In vitro and in vivo assessment of delivery of hydrophobic molecules and plasmid DNAs with PEO–PPO–PEO polymeric micelles on cornea

  2017cites this paper
• How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches

  2017cites this paper
• Predictive Modeling of Ocular Pharmacokinetics and Adverse Effects.

  2017cites this paper
• Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma.

  2016cites this paper
• In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery.

  2016influential citation